AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3893732 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72,222 (20-40 mg)
Number of subjects: 47
Study 3893732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29885997 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (CRT) with 3 cycles of cisplatin (100 mg/m2) concurrent with RT, followed by 3 cycles of cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/day for 4 days)
Number of subjects: 441
Study 29885997 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 441
Study 29885997 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (CRT) with 3 cycles of cisplatin (100 mg/m2) concurrent with RT
Number of subjects: 441
Study 29885997 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-fluorouracil (2 or more cycles)
Number of subjects: 441
Study 27668585 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided lumbosacral facet joint injection of methylprednisolone acetate (0.1 mg/kg)
Number of subjects: 15
Study 27668585 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided transforaminal epidural injection of methylprednisolone acetate (0.1 mg/kg)
Number of subjects: 15
Study 27668585 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided translaminar epidural injection of methylprednisolone acetate (0.1 mg/kg)
Number of subjects: 15
Study 24019126 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg orally, twice daily, 4 and 3 hours before each radiotherapy fraction
Number of subjects: 36
Study 24019126 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 36
Study 22464806 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU of vitamin D₃ every 20 days for 2 months)
Number of subjects: 50
Study 22464806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 every 20 days for 2 months)
Number of subjects: 50
Study 20305869 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% citric acid solution
Number of subjects: 150
Study 20305869 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% EDTA gel
Number of subjects: 150
Study 20305869 — intervention group
Group type: EXPERIMENTAL
Intervention: tetracycline solution (50 mg/mL)
Number of subjects: 150
Study 20305869 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sodium citrate solution
Number of subjects: 150
Study 20305869 — intervention group
Group type: COMPARATOR
Intervention: saline solution irrigation
Number of subjects: 150
Study 16732096 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid treatment
Number of subjects: 0
Study 16732096 — intervention group
Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 0
Study 16732096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15549690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St. John's Wort), duration of treatment not specified.
Number of subjects: 0
Study 15549690 — intervention group
Group type: COMPARATOR
Intervention: Not applicable, as the study mentions that beliefs did not mediate the effect of treatment on depression.
Number of subjects: 0
Study 11745221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg)
Number of subjects: 21
Study 11745221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9250141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus strain La1
Number of subjects: 28
Study 9250141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum strain Bb12
Number of subjects: 28
Study 8516819 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal IL‐2 receptor antibody therapy as part of a quadruple immunosuppressive regimen
Number of subjects: 66
Study 8516819 — intervention group
Group type: COMPARATOR
Intervention: ATG as induction therapy
Number of subjects: 66
Study 3572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancement of zygomatic EMG during positive scenes
Number of subjects: 30
Study 3572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of zygomatic EMG during positive scenes
Number of subjects: 30
Study 3572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancement of corrugator EMG during negative scenes
Number of subjects: 30
Study 3572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of corrugator EMG during negative scenes
Number of subjects: 30
Study 31392405 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic synthetic mesh in sublay position
Number of subjects: 211
Study 31392405 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic mesh
Number of subjects: 211
Study 27640089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm for appendicitis
Number of subjects: 866
Study 25248651 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcidiol (4000 IU per week)
Number of subjects: 66
Study 25248651 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (5000 IU per week)
Number of subjects: 66
Study 24830577 — intervention group
Group type: EXPERIMENTAL
Intervention: OSS plus SF‐ELS (split dose)
Number of subjects: 737
Study 24830577 — intervention group
Group type: EXPERIMENTAL
Intervention: OSS plus SF‐ELS (entire dose)
Number of subjects: 737
Study 24830577 — intervention group
Group type: COMPARATOR
Intervention: PEG‐EA (split dose)
Number of subjects: 737
Study 24830577 — intervention group
Group type: COMPARATOR
Intervention: Bisacodyl plus SF‐ELS (same-day preparation)
Number of subjects: 737
Study 24830577 — intervention group
Group type: EXPERIMENTAL
Intervention: OSS plus SF‐ELS
Number of subjects: 737
Study 22744541 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Massage (TM)
Number of subjects: 26
Study 22744541 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Tissue Massage (DTM)
Number of subjects: 26
Study 19407953 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with acitretin capsule
Number of subjects: 80
Study 19407953 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine alone
Number of subjects: 80
Study 19407953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Chinese herbal medicine with and without acitretin)
Number of subjects: 80
Study 17574073 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A)
Number of subjects: 1203
Study 17574073 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cisplatin (AP)
Number of subjects: 1203
Study 17574073 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/paclitaxel (AT)
Number of subjects: 1203
Study 17574073 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/doxorubicin/cisplatin (TAP)
Number of subjects: 1203
Study 17574073 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic type (S, CC, E)
Number of subjects: 1203
Study 17574073 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology (S, CC)
Number of subjects: 1203
Study 16264181 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of adjuvant tamoxifen therapy
Number of subjects: 4610
Study 16264181 — intervention group
Group type: COMPARATOR
Intervention: 2 years of adjuvant tamoxifen therapy
Number of subjects: 4610
Study 11875146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention focused on alcohol and tobacco use
Number of subjects: 3525
Study 11875146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention focused on gun safety, bicycle helmet, and seatbelt use
Number of subjects: 3525
Study 11875146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle helmet use intervention
Number of subjects: 3525
Study 11875146 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3525
Study 10901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV) drugs (zidovudine with or without lamivudine or nevirapine)
Number of subjects: 11
Study 10901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 11
Study 10901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic and nutritional interventions
Number of subjects: 11
Study 10901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential, voluntary HIV screening and counseling of pregnant women with short-course ARV treatment during the perinatal period
Number of subjects: 11
Study 10901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis using ARV drugs in newborns
Number of subjects: 11
Study 8848900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) administered continuously during 60 min
Number of subjects: 30
Study 8848900 — intervention group
Group type: COMPARATOR
Intervention: Control group (without SNP)
Number of subjects: 30
Study 1691806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin infusion (total 6.10(6) KIU) before and during bypass
Number of subjects: 82
Study 1691806 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of aprotinin (2.10(6) KIU) in the pump prime
Number of subjects: 82
Study 1691806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 451497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycerol solution
Number of subjects: 56
Study 451497 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose solution (placebo)
Number of subjects: 56
Study 31083231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.7 MBq I‐131/g thyroid plus 600 mg/day LiCO3
Number of subjects: 60
Study 31083231 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.55 MBq I‐131/g plus 600 mg/day LiCO3
Number of subjects: 60
Study 31083231 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.4 MBq I‐131/g without LiCO3
Number of subjects: 60
Study 31083231 — intervention group
Group type: COMPARATOR
Intervention: 7.4 MBq I‐131/g
Number of subjects: 60
Study 27725249 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief COPE
Number of subjects: 350
Study 25582309 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of iron (Fe) plus 30 mg of zinc (Zn) for 3 months
Number of subjects: 81
Study 25582309 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of zinc (Zn) plus 30 mg of iron (Fe) for 3 months
Number of subjects: 81
Study 25582309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 23580239 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 600 mg twice daily
Number of subjects: 101
Study 23580239 — intervention group
Group type: COMPARATOR
Intervention: best supportive care
Number of subjects: 101
Study 21767802 — intervention group
Group type: EXPERIMENTAL
Intervention: European Practice Assessment (EPA) at baseline (t1) and at the 3-year follow-up (t2)
Number of subjects: 102
Study 21767802 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (209 practices) beginning EPA at t2
Number of subjects: 102
Study 19211442 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent NSAID users (defined as >or=4 days per week)
Number of subjects: 850
Study 19211442 — intervention group
Group type: COMPARATOR
Intervention: Placebo subjects who later used NSAIDs sporadically (reference group)
Number of subjects: 850
Study 19211442 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin
Number of subjects: 850
Study 19211442 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin
Number of subjects: 850
Study 16895892 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 1140 mg/d
Number of subjects: 31
Study 16895892 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake range (700-2100 mg/d)
Number of subjects: 31
Study 15098883 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin, 0.5 mg/d subcutaneously (group A)
Number of subjects: 100
Study 15098883 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin, 3.75 mg depot (group B)
Number of subjects: 100
Study 15098883 — intervention group
Group type: COMPARATOR
Intervention: FSH only for ovarian stimulation
Number of subjects: 100
Study 12217220 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophic Stress Intervention (CSI)
Number of subjects: 1030
Study 12217220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1030
Study 9514532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation for 15 min
Number of subjects: 7
Study 9514532 — intervention group
Group type: COMPARATOR
Intervention: Baseline (pre-hyperventilation)
Number of subjects: 7
Study 9514532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 7
Study 8036680 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 15 mg for 14 days
Number of subjects: 167
Study 8036680 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 22.5 mg for 14 days
Number of subjects: 167
Study 8036680 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 300 mg on the first day
Number of subjects: 167
Study 8036680 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 450 mg on the first day
Number of subjects: 167
Study 2675651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg tablets taken four times a day for 4 to 6 days
Number of subjects: 68
Study 2675651 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 68
Study 1266277 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 25 mg (22.1 mg free base)
Number of subjects: 18
Study 1266277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetacrine 33.5 mg (21.4 mg free base)
Number of subjects: 18
Study 1266277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 18
Study 1266277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants during ergometric exercise
Number of subjects: 18
Study 31945895 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR glycemic control framework (full version)
Number of subjects: 0
Study 31945895 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR-IO (insulin only version)
Number of subjects: 0
Study 31945895 — intervention group
Group type: COMPARATOR
Intervention: Standard unit protocol (control group)
Number of subjects: 0
Study 28189364 — intervention group
Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg EPA‐ethyl esters and DHA‐EEs)
Number of subjects: 0
Study 28189364 — intervention group
Group type: COMPARATOR
Intervention: Lovaza (3600 mg ω‐3)
Number of subjects: 0
Study 25263410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal-Psychological Theory of Suicidal Behavior (IPTS) constructs: Thwarted Belongingness (TB), Perceived Burdensomeness (PB), Acquired Capability (AC)
Number of subjects: 376
Study 25263410 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired Capability (AC)
Number of subjects: 376
Study 22277329 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV6/11/16/18 exposure risk assessment
Number of subjects: 2409
Study 22277329 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 antibody or DNA testing
Number of subjects: 2409
Study 22277329 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 dual positivity testing
Number of subjects: 2409
Study 22277329 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of risk factors for HPV positivity
Number of subjects: 2409
Study 22277329 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of HPV6/11 and 16/18 DNA positivity
Number of subjects: 2409
Study 22277329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia infection analysis
Number of subjects: 2409
Study 20237169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg)
Number of subjects: 5238
Study 18324469 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention (training in HIV prevention for 4.5 days and malaria for 0.5 days)
Number of subjects: 568
Study 18324469 — intervention group
Group type: COMPARATOR
Intervention: Control condition (reverse training)
Number of subjects: 568
Study 15479752 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal scalpel debridement (NCT group)
Number of subjects: 38
Study 15479752 — intervention group
Group type: COMPARATOR
Intervention: Sham scalpel debridement (SCT group)
Number of subjects: 38
Study 12458369 — intervention group
Group type: EXPERIMENTAL
Intervention: High resistance-training group (n=10)
Number of subjects: 19
Study 12458369 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 19
Study 10332441 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily controlled release oxybutynin
Number of subjects: 105
Study 10332441 — intervention group
Group type: COMPARATOR
Intervention: Immediate release oxybutynin
Number of subjects: 105
Study 8622042 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF (granulocyte [G]- or granulocyte-macrophage [GM]-CSF)
Number of subjects: 54
Study 8622042 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (cumulative dose in the first cycle)
Number of subjects: 54
Study 8622042 — intervention group
Group type: COMPARATOR
Intervention: No CSF
Number of subjects: 54
Study 1777913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg 3 times daily)
Number of subjects: 19
Study 1777913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6811379 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 250 μg combined with 30 μg ethinyl estradiol
Number of subjects: 5
Study 6811379 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 250 μg combined with 20 μg ethinyl estradiol
Number of subjects: 5
Study 31395750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause with explicit timeline
Number of subjects: 597
Study 31395750 — intervention group
Group type: COMPARATOR
Intervention: Cause only
Number of subjects: 597
Study 31395750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause with basic timeline
Number of subjects: 597
Study 31395750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause with explicit timeline for women with 4‐10 lifetime partners
Number of subjects: 597
Study 30762782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread-embedding acupuncture (TEA)
Number of subjects: 56
Study 30762782 — intervention group
Group type: COMPARATOR
Intervention: Sham thread-embedding acupuncture (STEA)
Number of subjects: 56
Study 28459717 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) via a novel negative pressure device
Number of subjects: 44
Study 28459717 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound dressing (wet to moist gauze)
Number of subjects: 44
Study 25425219 — intervention group
Group type: EXPERIMENTAL
Intervention: L-RISK diet (high in cereal fibre: 30-50 g/day and coffee: ≥ 5 cups/day, free of red meat)
Number of subjects: 37
Study 25425219 — intervention group
Group type: COMPARATOR
Intervention: H-RISK diet (low in fibre: ≤ 10 g/day, coffee-free, high in red meat: ≥ 150 g/day)
Number of subjects: 37
Study 24676435 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (30 minutes, twice a week, moderate intensity of 60% VO₂max)
Number of subjects: 20
Study 24676435 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 20
Study 21647811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga sessions based upon the Yoga Ed program for 11 weeks
Number of subjects: 0
Study 21647811 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education classes
Number of subjects: 0
Study 18562423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 24
Study 18562423 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 24
Study 17450988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bussed tables (leftover wings removed)
Number of subjects: 50
Study 17450988 — intervention group
Group type: COMPARATOR
Intervention: Unbussed tables (wings left on table)
Number of subjects: 50
Study 16987186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-marking using a model answer
Number of subjects: 289
Study 16987186 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control arm)
Number of subjects: 289
Study 12764907 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr alone (Sr)
Number of subjects: 126
Study 12764907 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr combined with Guliu recipe (Sr-GLR)
Number of subjects: 126
Study 10715622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 ppm ozone exposure
Number of subjects: 19
Study 8799520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral strontium chloride administration under fasting conditions (study I)
Number of subjects: 16
Study 8799520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral strontium chloride administration with a standardized meal (study II)
Number of subjects: 16
Study 8799520 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of strontium with a meal
Number of subjects: 16
Study 1732370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 74
Study 1732370 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 74
Study 1732370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Propranolol
Number of subjects: 74
Study 1732370 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 74
Study 6503256 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic fields generated by a device (4 X 10(‐4) T, frequency range 1‐1000 Hz)
Number of subjects: 0
Study 6503256 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31202812 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of vinegar
Number of subjects: 0
Study 31202812 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acetate
Number of subjects: 0
Study 31202812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar
Number of subjects: 0
Study 27341068 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance and balance exercise program (twice weekly for three months)
Number of subjects: 43
Study 27341068 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 26556078 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 40
Study 26556078 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS combined with MVC
Number of subjects: 40
Study 24124331 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion at 0 kcal/min
Number of subjects: 15